Davis Polk & Wardwell advised Ultra Clean Holdings, Inc. on the transaction. Ultra Clean Holdings, Inc. (UCT) announced its acquisition of HIS Innovations Group. UCT paid $50...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised IDEAYA Biosciences, Inc. on the offering, and Davis Polk & Wardwell advised the representatives of the several underwriters. IDEAYA Biosciences, Inc. (NASDAQ:IDYA)...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell advised GSK on the deal. 23andMe Holding Co. (Nasdaq: ME) (“23andMe”) announced a new non-exclusive data license with GSK plc (LSE/NYSE: GSK) which...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell is advising Roche on the transaction, and Freshfields Bruckhaus Deringer is advising Roivant. Roivant (Nasdaq: ROIV) announced it has entered into a definitive...
You must be a Standard 1 Year member to access this content.
Gide Loyrette Nouel and Cooley represented Inventiva S.A. on the offering. Davis Polk & Wardwell and Linklaters TD advised Cowen, as the sales agent. Inventiva S.A....
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell advised the representatives of the several initial purchasers on the offering. Advanced Energy Industries, Inc. (Nasdaq: AEIS) announced the closing of its previously announced...
You must be a Standard 1 Year member to access this content.
Simpson Thacher & Bartlett advised CSG Systems International, Inc., and Davis Polk & Wardwell advised the representatives of the initial purchasers on the offering. CSG Systems...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell represented the initial purchasers in the offering. Tetra Tech, Inc. announced its Rule 144A offering of $575 million aggregate principal amount of its 2.25%...
You must be a Standard 1 Year member to access this content.
Cooley advised AN2 Therapeutics, Inc., and Davis Polk & Wardwell advised the joint book-running managers on the offering. AN2 Therapeutics, Inc. (Nasdaq:ANTX) announced a SEC-registered follow-on...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised NGM Biopharmaceuticals, while Davis Polk & Wardwell advised Jefferies, as sales agent in the offering. NGM Biopharmaceuticals (NASDAQ:NGM) announced its common stock for up to...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell advised Immedica Pharma AB on the transaction. Immedica Pharma AB announced its acquisition from Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) of all assets related...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell advised Immatics N.V. in the deal. Immatics N.V. announced its $35 million private placement of ordinary shares. All of the shares were purchased...
You must be a Standard 1 Year member to access this content.
